PubRank

Junzo Kigawa

Author PubWeight™ 65.06‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Mechanisms of chemoresistance and poor prognosis in ovarian clear cell carcinoma. Cancer Sci 2008 1.83
2 Functional assessment of ABCG2 (BCRP) gene polymorphisms to protein expression in human placenta. Drug Metab Dispos 2004 1.41
3 Detection of peritoneal dissemination in gynecological malignancy: evaluation by diffusion-weighted MR imaging. Eur Radiol 2007 1.25
4 Ovarian metastasis in carcinoma of the uterine cervix. Gynecol Oncol 2005 1.24
5 Low proliferation activity may be associated with chemoresistance in clear cell carcinoma of the ovary. Obstet Gynecol 2002 1.18
6 Intraperitoneal carboplatin infusion may be a pharmacologically more reasonable route than intravenous administration as a systemic chemotherapy. A comparative pharmacokinetic analysis of platinum using a new mathematical model after intraperitoneal vs. intravenous infusion of carboplatin--a Sankai Gynecology Study Group (SGSG) study. Gynecol Oncol 2005 1.14
7 Diagnostic accuracy of diffusion-weighted imaging in differentiating benign from malignant ovarian lesions. J Magn Reson Imaging 2008 1.14
8 Clinicopathological characteristics of mucinous adenocarcinoma of the ovary. Gynecol Oncol 2009 1.07
9 Sensitivity to anticancer agents and resistance mechanisms in clear cell carcinoma of the ovary. Jpn J Cancer Res 2002 1.05
10 Glutathione peroxidase 3 is a candidate mechanism of anticancer drug resistance of ovarian clear cell adenocarcinoma. Oncol Rep 2008 1.03
11 Haplotype-oriented genetic analysis and functional assessment of promoter variants in the MDR1 (ABCB1) gene. J Pharmacol Exp Ther 2004 1.02
12 Diagnostic accuracy of the apparent diffusion coefficient in differentiating benign from malignant uterine endometrial cavity lesions: initial results. Eur Radiol 2007 1.02
13 Adjuvant chemotherapy with irinotecan hydrochloride and cisplatin for clear cell carcinoma of the ovary. Oncol Rep 2006 1.01
14 Regulation of autophagy and its associated cell death by "sphingolipid rheostat": reciprocal role of ceramide and sphingosine 1-phosphate in the mammalian target of rapamycin pathway. J Biol Chem 2012 1.00
15 Multidrug resistance gene-1 is a useful predictor of Paclitaxel-based chemotherapy for patients with ovarian cancer. Gynecol Oncol 2002 1.00
16 A randomized Phase II/III trial of 3 weekly intraperitoneal versus intravenous carboplatin in combination with intravenous weekly dose-dense paclitaxel for newly diagnosed ovarian, fallopian tube and primary peritoneal cancer. Jpn J Clin Oncol 2010 0.98
17 Objective evaluation of the alleviating effects of Goshajinkigan on peripheral neuropathy induced by paclitaxel/carboplatin therapy: A multicenter collaborative study. Exp Ther Med 2011 0.98
18 Expression of the c-myc gene as a predictor of chemotherapy response and a prognostic factor in patients with ovarian cancer. Cancer Sci 2004 0.97
19 Phase II study of intraperitoneal carboplatin with intravenous paclitaxel in patients with suboptimal residual epithelial ovarian or primary peritoneal cancer: a Sankai Gynecology Cancer Study Group Study. Int J Gynecol Cancer 2009 0.93
20 Phase II clinical trial of pegylated liposomal doxorubicin (JNS002) in Japanese patients with mullerian carcinoma (epithelial ovarian carcinoma, primary carcinoma of fallopian tube, peritoneal carcinoma) having a therapeutic history of platinum-based chemotherapy: a Phase II Study of the Japanese Gynecologic Oncology Group. Jpn J Clin Oncol 2008 0.93
21 Inhibiting the mTOR pathway synergistically enhances cytotoxicity in ovarian cancer cells induced by etoposide through upregulation of c-Jun. Clin Cancer Res 2011 0.92
22 Combination chemotherapy of oxaliplatin and 5-fluorouracil may be an effective regimen for mucinous adenocarcinoma of the ovary: a potential treatment strategy. Cancer Sci 2008 0.92
23 Checkpoint kinase inhibitor AZD7762 overcomes cisplatin resistance in clear cell carcinoma of the ovary. Int J Gynecol Cancer 2014 0.92
24 Questionnaire survey of the current status of radical trachelectomy in Japan. Int J Clin Oncol 2010 0.91
25 PTEN-positive and phosphorylated-Akt-negative expression is a predictor of survival for patients with advanced endometrial carcinoma. Oncol Rep 2005 0.91
26 PTEN expression is associated with prognosis for patients with advanced endometrial carcinoma undergoing postoperative chemotherapy. Int J Cancer 2002 0.90
27 Nedaplatin: a cisplatin derivative in cancer chemotherapy. Cancer Manag Res 2013 0.90
28 Mechanisms of cisplatin resistance in clear cell carcinoma of the ovary. Oncology 2002 0.89
29 Novel mechanism of reduced proliferation in ovarian clear cell carcinoma cells: cytoplasmic sequestration of CDK2 by p27. Gynecol Oncol 2011 0.89
30 Progression-free survival and overall survival of patients with clear cell carcinoma of the ovary treated with paclitaxel-carboplatin or irinotecan-cisplatin: retrospective analysis. Int J Clin Oncol 2007 0.89
31 MEK1/2 inhibitor selumetinib (AZD6244) inhibits growth of ovarian clear cell carcinoma in a PEA-15-dependent manner in a mouse xenograft model. Mol Cancer Ther 2011 0.89
32 The impact of complete surgical staging upon survival in early-stage ovarian clear cell carcinoma: a multi-institutional retrospective study. Int J Gynecol Cancer 2009 0.88
33 Regulation of cell migration by sphingomyelin synthases: sphingomyelin in lipid rafts decreases responsiveness to signaling by the CXCL12/CXCR4 pathway. Mol Cell Biol 2012 0.87
34 Leptomycin B enhances CDDP-sensitivity via nuclear accumulation of p53 protein in HPV-positive cells. Cancer Sci 2003 0.87
35 Histological grading of ovarian clear cell adenocarcinoma: proposal for a simple and reproducible grouping system based on tumor growth architecture. Int J Gynecol Pathol 2012 0.86
36 Phase II study of combination chemotherapy with docetaxel and carboplatin for locally advanced or recurrent cervical cancer. Int J Gynecol Cancer 2010 0.86
37 Activation of the mitogen-activated protein kinase kinase/extracellular signal-regulated kinase pathway overcomes cisplatin resistance in ovarian carcinoma cells. Int J Gynecol Cancer 2012 0.85
38 Chemotherapy consisting of paclitaxel and carboplatin benefits a patient with malignant mixed müllerian tumor of the fallopian tube. Int J Clin Oncol 2008 0.85
39 Clear cell adenocarcinoma with a component of poorly differentiated histology: a poor prognostic subgroup of ovarian clear cell adenocarcinoma. Int J Gynecol Pathol 2011 0.85
40 PTEN is involved in the signal transduction pathway of contact inhibition in endometrial cells. Cell Tissue Res 2005 0.84
41 Adenovirus type 5 E1A gene therapy for ovarian clear cell carcinoma: a potential treatment strategy. Mol Cancer Ther 2007 0.84
42 Clinical trials and future potential of targeted therapy for ovarian cancer. Int J Clin Oncol 2012 0.83
43 Transvaginal ultrasonography and endometrial cytology as a diagnostic schema for endometrial cancer. Gynecol Obstet Invest 2005 0.83
44 Evidence-based guidelines for treatment of uterine body neoplasm in Japan: Japan Society of Gynecologic Oncology (JSGO) 2009 edition. Int J Clin Oncol 2010 0.83
45 Myometrial invasion by endometrial carcinoma: evaluation with 3.0T MR imaging. Abdom Imaging 2011 0.82
46 Differential expression of hypoxia-inducible protein 2 among different histological types of epithelial ovarian cancer and in clear cell adenocarcinomas. Int J Gynecol Cancer 2010 0.82
47 Applicability of the concept of "platinum sensitivity" to recurrent endometrial cancer: the SGSG-012/GOTIC-004/Intergroup study. Gynecol Oncol 2013 0.82
48 A phase II clinical trial of topotecan in Japanese patients with relapsed ovarian carcinoma. Jpn J Clin Oncol 2010 0.82
49 Prediction of individual response to platinum/paclitaxel combination using novel marker genes in ovarian cancers. Mol Cancer Ther 2006 0.81
50 Paclitaxel-carboplatin for advanced or recurrent carcinosarcoma of the uterus: the Japan Uterine Sarcoma Group and Tohoku Gynecologic Cancer Unit Study. Int J Clin Oncol 2014 0.81
51 A feasibility study on biweekly administration of docetaxel for patients with recurrent ovarian cancer. Gynecol Oncol 2003 0.80
52 Correlation of apparent diffusion coefficient value with prognostic parameters of endometrioid carcinoma. J Magn Reson Imaging 2013 0.80
53 Area under the curve calculation of nedaplatin dose used in combination chemotherapy with irinotecan in a phase I study of gynecologic malignancies. Cancer Chemother Pharmacol 2012 0.79
54 Timing of G-CSF administration based on the circadian rhythm in patients with ovarian cancer. Am J Clin Oncol 2002 0.79
55 Outcome of stage IB2-IIB patients with bulky uterine cervical cancer who underwent neoadjuvant chemotherapy followed by radical hysterectomy. Int J Clin Oncol 2013 0.79
56 Establishment and characterization of a novel ovarian clear cell adenocarcinoma cell line, TU-OC-1, with a mutation in the PIK3CA gene. Hum Cell 2013 0.79
57 Ovarian endometrioid adenocarcinoma arising from endometriosis in a young woman. Gynecol Oncol 2003 0.79
58 Dual inhibition of phosphatidylinositol 3'-kinase and mammalian target of rapamycin using NVP-BEZ235 as a novel therapeutic approach for mucinous adenocarcinoma of the ovary. Int J Gynecol Cancer 2014 0.79
59 Identification of potential serum markers for endometrial cancer using protein expression profiling. J Cancer Res Clin Oncol 2009 0.79
60 Clinical impact of systematic pelvic and para-aortic lymphadenectomy for pT1 and pT2 ovarian cancer: a retrospective survey by the Sankai Gynecology Study Group. Int J Clin Oncol 2012 0.78
61 Apparent diffusion coefficient (ADC) measurement in endometrial carcinoma: effect of region of interest methods on ADC values. J Magn Reson Imaging 2013 0.78
62 The benefit of chemotherapy in a patient with multiple brain metastases and meningitis carcinomatosa from ovarian cancer. Int J Clin Oncol 2005 0.78
63 Evaluation of a formula for individual dosage of nedaplatin based on renal function. Cancer Chemother Pharmacol 2011 0.78
64 Activity of docetaxel in paclitaxel-resistant ovarian cancer cells. Cancer Chemother Pharmacol 2003 0.78
65 Simultaneous inhibition of the mitogen-activated protein kinase kinase and phosphatidylinositol 3'-kinase pathways enhances sensitivity to paclitaxel in ovarian carcinoma. Cancer Sci 2007 0.78
66 Stromal invasion of the cervix can be excluded from the criteria for using adjuvant radiotherapy following radical surgery for patients with cervical cancer. Gynecol Oncol 2004 0.78
67 Psychological Factors and Characteristics of Recurrent Breast Cancer Patients with or without Psychosocial Group Therapy Intervention. Yonago Acta Med 2011 0.78
68 Feasibility Study of Adjuvant Chemotherapy Using Taxane Plus Carboplatin for High-Risk Patients With Uterine Cervical Non-Squamous Cell Carcinoma After Radical Hysterectomy. Int J Gynecol Cancer 2016 0.77
69 Establishment and characterization of a novel ovarian serous adenocarcinoma cell line, TU-OS-4, that overexpresses EGFR and HER2. Hum Cell 2012 0.77
70 Validation of the histologic grading for ovarian clear cell adenocarcinoma: a retrospective multi-institutional study by the Japan Clear Cell Carcinoma Study Group. Int J Gynecol Pathol 2011 0.77
71 Less impact of adjuvant chemotherapy for stage I clear cell carcinoma of the ovary: a retrospective Japan Clear Cell Carcinoma Study. Int J Gynecol Cancer 2010 0.77
72 Incidence and risk factors for lower limb lymphedema after gynecologic cancer surgery with initiation of periodic complex decongestive physiotherapy. Int J Clin Oncol 2014 0.76
73 Fibroblast growth factor receptor 2 is associated with poor overall survival in clear cell carcinoma of the ovary and may be a novel therapeutic approach. Int J Gynecol Cancer 2015 0.75
74 Contribution of transcription factor, SP1, to the promotion of HB-EGF expression in defense mechanism against the treatment of irinotecan in ovarian clear cell carcinoma. Cancer Med 2014 0.75
75 Preoperative and intraoperative assessments of depth of myometrial invasion in endometrial cancer. Int J Gynecol Cancer 2009 0.75
76 Chemoresistance of Gastric-Type Mucinous Carcinoma of the Uterine Cervix: A Study of the Sankai Gynecology Study Group. Int J Gynecol Cancer 2017 0.75
77 Feasibility study on biweekly paclitaxel treatment as maintenance chemotherapy in advanced müllerian carcinoma. Gynecol Obstet Invest 2012 0.75
78 Relationship between ABCF2 expression and response to chemotherapy or prognosis in clear cell adenocarcinoma of the ovary. Int J Gynecol Cancer 2010 0.75
79 [Molecular targeted therapies for epithelial ovarian cancer]. Nihon Rinsho 2012 0.75
80 [Lymphadenectomy for cervical cancer: indications and limits]. Nihon Rinsho 2004 0.75
81 [PTEN expression in endometrial cancer and the prognosis]. Nihon Rinsho 2004 0.75
82 [Preservation of organic function in surgery for cervical cancer]. Nihon Rinsho 2004 0.75
83 Feasibility study comparing docetaxel-cisplatin versus docetaxel-carboplatin as first-line chemotherapy for ovarian cancer. Gynecol Oncol 2006 0.75
84 Clinicopathologic study of 56 patients with endometrial cancer during or after adjuvant tamoxifen use for their breast cancers. Gynecol Oncol 2004 0.75
85 Hydrotubation for diagnosing carcinoma in situ of the fallopian tube. A case report. Acta Cytol 2002 0.75
86 Pseudo-Meigs' syndrome caused by retroperitoneal tumor in a patient with Ebstein anomaly. Int J Clin Oncol 2005 0.75
87 What is an appropriate second-line regimen for recurrent endometrial cancer? Ancillary analysis of the SGSG012/GOTIC004/Intergroup study. Cancer Chemother Pharmacol 2015 0.75